NASDAQ$NKTX
Nkarta Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Nkarta reported financial results for the fourth quarter and year ended December 31, 2023.
Nkarta's pipeline realignment focuses resources on rapid advancement of NKX019 in autoimmune diseases and deprioritizes development of NKX101. The company had $250.9 million in cash, cash equivalents and investments as of year-end 2023, which is anticipated to fund operations into 2026.
- First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletion
- Additional B-cell mediated autoimmune diseases under consideration for broader clinical investigation of NKX019
- Pipeline realignment focuses resources on rapid advancement of NKX019 in autoimmune diseases and deprioritizes development of NKX101
- 2023 year-end cash, cash equivalents and investments of $250.9 million
Headline financials
Revenue & EPS history
Nkarta · Revenue · Quarterly
$10.5M
Forward guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2023
+0.9%
Avg return
Earnings day
-2.2%
Avg return
5 days after
-0.9%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+16.2%
Q4 2021
Best reaction
-30.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.9% | -14.8% | — | |
| Q1 2026 | +3.5% | -16.1% | -13.2% | |
| Q3 2025 | +3.1% | -4.6% | -4.6% | |
| Q2 2025 | +12.8% | +19.9% | +0.5% | |
| Q1 2025 | +1.2% | -0.6% | -4.6% | |
| Q4 2024 | +3.2% | -15.4% | +13.3% | |
| Q3 2024 | -4.8% | -9.0% | -23.0% | |
| Q2 2024 | +1.2% | +0.0% | +10.3% | |
| Q1 2024 | -2.3% | +2.3% | +3.1% | |
| Q4 2023 | -30.3% | -22.8% | -43.0% | |
| Q3 2023 | -5.6% | +7.0% | +27.0% | |
| Q2 2023 | -0.5% | -1.0% | -20.5% | |
| Q1 2023 | -4.1% | -4.1% | -0.9% | |
| Q4 2022 | +1.3% | -7.1% | +19.3% | |
| Q3 2022 | -8.4% | -2.1% | -35.5% | |
| Q2 2022 | +8.8% | +11.1% | -8.5% | |
| Q1 2022 | +12.8% | +11.1% | +6.9% | |
| Q4 2021 | +16.2% | +6.2% | -15.2% | |
| Q3 2021 | +7.7% | +7.2% | -15.0% | |
| Q2 2021 | -1.9% | -5.0% | -29.0% | |
| Q4 2020 | +0.0% | -14.4% | -30.3% | |
| Q3 2020 | +2.9% | +14.5% | +122.0% | |
| Q2 2020 | -7.0% | -12.0% | +21.1% | |
| Q1 2021 | +11.3% | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro